BeiGene files patent suits against San­doz, MSN Group

BeiGene cel­e­brat­ed its fifth in­di­ca­tion for Brukin­sa with a law­suit.

A day af­ter win­ning an ac­cel­er­at­ed ap­proval in fol­lic­u­lar lym­phoma, BeiGene filed com­plaints against San­doz and sub­sidiaries of MSN Group over ap­pli­ca­tions to mar­ket gener­ic ver­sions of Brukin­sa. The com­pa­ny claims that San­doz and MSN in­fringed patents on the blood can­cer block­buster and has asked the court to bar San­doz and MSN from com­mer­cial­iz­ing their gener­ics un­til the patents ex­pire.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER